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To better control the “licensing” of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic
ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and
costimulatory signaling elements, permitting DC regulation in vivo within the context of an immunological synapse.
This novel technology results in potent anti-cancer activity.
Due mostly to their predominant role as
antigen-presenting cells (APCs) for the
induction of naïve T cells, autologous
dendritic cells (DCs) have been the focus
of over 200 clinical trials as cellular
adjuvants for neoplastic disease. Neverthe-
less, objective response rates remain
modest in the 10% range.
1 Since their
discovery in the early 70s,
2 it has become
increasingly apparent that the activation
state of DCs is critical for differentiating
between the pro-tolerogenic state of
immature DCs and the highly immuno-
genic state of activated or “licensed” DCs.
Likewise, a panoply of pro-immunogenic
cocktails have been devised to maximize ex
vivo activation of autologous DCs, includ-
ing so-called monocyte-derived “matura-
tion cocktail” (i.e., TNFa, IL1β, IL-6 and
PGE2) or newer protocols that substitute
Type I interferons and other adjuvants for
IL-12p70-suppressing PGE2, leading typi-
cally to faster differentiation and higher
IL-12 secretion (reviewed in ref. 3).
Despite improvements, ex vivo-matured
DCs have still failed to reflect significant
tumor responses, possible due to pre-
mature or transient release of pro-Th1
cytokines, like IL-12, in culture concomi-
tant with activation, prior to arrival in
draining LNs in a pro-Th2 state.
4
Alternative approaches that rely on DC
activation in vivo using systemic adjuvants
(e.g., poly(dI-dC), CD40L) after admin-
istration of immature or partially mature
DCs may circumvent this problem, but
instead run the risk of immune activation
of untargeted DCs or activating non-DCs
with deleterious sequelae. Activated non-
targeted APCs, lacking tumor antigen,
potentially increase the risk of autoimmu-
nity or diluting out the desired adaptive
immune response. Therefore, the ideal
vaccine would ensure that antigen expres-
sion and DC activation are coordinated
and occur in a spatiotemporally regulated
manner.
To circumvent the challenges of regu-
lated activation of antigen-primed DCs,
we have developed a synthetic ligand-
inducible adjuvant, called “iMyD88/
CD40” (or “iMC”), which combines
TLR/IL1R signaling with synergistic
CD40 signaling, leading to very high
levels of ligand-regulated IL-12p70 secre-
tion and potent antigen-specific, anti-
tumor responses in vivo (Fig.1).
5 As
opposed to other methods that fully
activate autologous DCs ex-vivo often
24 h or more before cryopreservation,
our method permits control over the
timing of DC activation, allowing LN
migration and potential cognate T cell
interaction to occur prior to release of
high-level IL-12. To achieve this level of
control, we have adapted the chemically
induced dimerization (CID) method to
the regulation of CD40 and TLR signal-
ing. In CID, signaling domains, like the
cytoplasmic domain of CD40 (CD40c;
residues 216–277), are fused to the 12
kDa, FK506-binding protein, FKBP12.
6
A Phe to Val point mutation at residue
36 of FKBP12 further ensures high
affinity (~0.1 nM) and high specificity
binding to the membrane-permeable,
synthetic homodimeric ligands, AP1903
or non-clinical analog, AP20187.
7 Addi-
tional sequences, like a myristoylation-
targeting (Myr) sequence can be added
to redirect chimeric fusion proteins to
subcellular locations, like the plasma
membrane. In iMC, a second mem-
brane-proximal signaling domain derived
from the “universal” TLR/IL1R adaptor,
MyD88, follows the Myr domain and
precedes the CD40c and tandem
FKBP12v36 domains.
In order to efficiently produce iMC-
expressing autologous DCs (iMC-DCs),
in Narayanan et al. we used Ad5 or
Ad5f35-pseudotyped adenovectors to
transduce mouse bone marrow-derived
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derived DCs (MoDCs), respectively.
Following addition of AP1903 to both
murine and human iMC-DCs, we
observed the strong phosphorylation and
hence induction of multiple signaling
molecules known to be involved in TLR
and CD40 signaling, including ERK,
JNK, p38, Akt, IKK a/β and several
NFkB subunits (i.e., p65/RelA, RelB,
c-Rel). Moreover, induction of these
pro-inflammatory signaling pathways
correlated with elaboration of both IL-
12p70 and other pro-inflammatory
cytokines. We also observed high-level
induction of maturation markers, such as
CD40, CD86, MHC class II and CCR7,
on AP1903-treated iMC-DCs, supporting
the contention that CID-treated DCs were
highly activated. Upregulation of CCR7
also correlated with increased migratory
ability in vitro and in vivo.
Finally, we demonstrated that tumor
antigen and dimerizer ligand-exposed
iMC-DCs had significantly better
immunogenicity against aggressive pre-
established B16 tumors relative to
CD40L/LPS-stimulated DCs. Moreover,
iMC-DCs were also more immunogenic
than DCs activated with CID-inducible
CD40 (iCD40) plus LPS (i.e., iCD40-
DCs). Our previous studies based on
iCD40-DCs were the first to investigate
the improved immunogenicity of tumor
antigen-exposed DCs that could be
targeted for activation following migration
to lymph nodes without reliance on
systemic adjuvants.
8 A phase I/IIa clinical
trial, sponsored by Bellicum Pharmaceuti-
cals, based on the use of prostate specific
membrane antigen (PSMA) pulsed,
iCD40-DCs (transiently exposed to LPS)
in metastatic, castration-resistant prostate
cancer (mCRPC) patients (BPX-101) is
close to conclusion and reveals that
iCD40-DCs appear safe and can trigger
objective anti-tumor responses in these late
stage cancer patients.
9 Use of chimeric
iMC-DCs promises to be both simpler
(obviating the need for transient TLR
ligand) and more efficacious, driving the
design on Next Generation vaccines.
In addition to efficacy, a number of
factors will determine the practicality of
deploying a broadly applicable DC-based
vaccine. These include portability and
scalability. By converting DC vaccines to
a regulatable genetic element that can be
co-expressed with tumor antigen(s), iMC
technology moves DC vaccines closer to a
viral or non-viral “off-the-shelf” weapon
against cancer and potentially other patho-
genic conditions. Although DC targeting
in vivo is a desirable accoutrement to this
technology, the high-level, pre-existing
efficiency by which DCs take up small
particles from their environment portends
that this new drug may already be at hand.
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Figure1. Schematic of iMyD88/CD40 (iMC) activation. To adapt TLR and CD40 signaling to control
by membrane-permeable, synthetic dimerizer drugs (i.e., AP1903 and AP20187), The cytoplasmic
domain of CD40 and a TIR domain-deleted version of MyD88 were fused adjacent to tandem copies
of the modified 12 kDa FK506 binding protein (FKBP12V36) and a myristoylation-targeting
sequence. Administration of dimerizer drug in vivo leads to rapid iMC oligomerization in iMC-
expressing DCs, resulting in induction of synergistic pro-inflammatory signaling pathways and
ultimately DC activation.
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